Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



23<sup>rd</sup> August 2024

Scrip Code: BSE - AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ		
Mumbai - 400 001	Bandra (East), Mumbai - 400 051		
Dalal Street,	G block, Bandra Kurla Complex,		
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/l,		
BSE Limited	National Stock Exchange of India		

Sub.: Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Dear Sir/Madam,

Pursuant to Regulation 39(3) of the SEBI LODR Regulations and in terms of SEBI Circular No. SEBI/HO/MIRSD/ MIRSD\_RTAMB/P/CIR/2022/8 dated 25<sup>th</sup> January, 2022, the Company has approved issuance of "Letter of Confirmation" on 23<sup>rd</sup> August 2024 in lieu of share certificate(s), which were reported lost by the following shareholder:

Name of Shareholder	Folio No	Old Certificate No.	New Certificate No.	Distinctive Nos.	Shares
JITENDRAKUMAR BAGDIYA	0000287	79	19561	58251- 59000	750

Kindly take the above information on record.

Thanking you,

Yours faithfully,

## **Gaurang Shah**

Sr. VP- Legal & Company Secretary